NewEdge Wealth LLC Buys 5,591 Shares of Sanofi (NASDAQ:SNY)

NewEdge Wealth LLC grew its position in Sanofi (NASDAQ:SNY - Free Report) by 20.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,799 shares of the company's stock after purchasing an additional 5,591 shares during the quarter. NewEdge Wealth LLC's holdings in Sanofi were worth $1,582,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Abel Hall LLC raised its holdings in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock worth $530,000 after acquiring an additional 194 shares during the period. PDS Planning Inc increased its stake in shares of Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company's stock worth $383,000 after purchasing an additional 200 shares during the period. Financial Advocates Investment Management increased its stake in shares of Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company's stock worth $365,000 after purchasing an additional 206 shares during the period. Angeles Investment Advisors LLC lifted its position in shares of Sanofi by 1.9% during the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company's stock worth $653,000 after purchasing an additional 210 shares during the last quarter. Finally, Keudell Morrison Wealth Management boosted its stake in Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after purchasing an additional 217 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY traded up $2.16 on Monday, reaching $56.63. 2,952,241 shares of the stock traded hands, compared to its average volume of 2,402,073. The stock's 50-day moving average price is $51.65 and its 200-day moving average price is $52.59. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market cap of $143.71 billion, a price-to-earnings ratio of 22.74, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on SNY shares. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Sanofi has a consensus rating of "Buy" and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.